[go: up one dir, main page]

WO2009120002A3 - Percutaneous preparation containing donepezil as active ingredient for treatment of dementia - Google Patents

Percutaneous preparation containing donepezil as active ingredient for treatment of dementia Download PDF

Info

Publication number
WO2009120002A3
WO2009120002A3 PCT/KR2009/001472 KR2009001472W WO2009120002A3 WO 2009120002 A3 WO2009120002 A3 WO 2009120002A3 KR 2009001472 W KR2009001472 W KR 2009001472W WO 2009120002 A3 WO2009120002 A3 WO 2009120002A3
Authority
WO
WIPO (PCT)
Prior art keywords
active ingredient
dementia
preparation
donepezil
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2009/001472
Other languages
French (fr)
Korean (ko)
Other versions
WO2009120002A2 (en
Inventor
최영권
이정식
김성수
구혜란
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ICURE Pharmaceutical Inc
Original Assignee
ICURE Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ICURE Pharmaceutical Inc filed Critical ICURE Pharmaceutical Inc
Publication of WO2009120002A2 publication Critical patent/WO2009120002A2/en
Publication of WO2009120002A3 publication Critical patent/WO2009120002A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a percutaneous preparation containing donepezil as an active ingredient for treatment of dementia. More specifically, the percutaneous preparation comprising donepezil as the active ingredient consists of a matrix layer containing drugs, a support layer for protecting the drugs, and a release layer. The matrix layer containing drugs comprises: donepezil or pharmaceutically acceptable salts thereof as the active ingredient; polyethylene vinyl acetate adhesives including rosin ester resin as a polymer substrate; and a penetration enhancer mixture of at least two kinds selected from the group consisting of pyrrolidone derivatives, C8-18 aliphatic derivatives, triacetin and triethyl citrate. The disclosed percutaneous preparation can increase dementia patient administration compliance and minimize side effects when compared with an oral preparation. Additionally, the percutaneous preparation is easily applied to skin and can release the drugs sustainably for a long time. Also, due to high skin-penetration properties, the preparation can replace conventional oral preparations for treatment of dementia.
PCT/KR2009/001472 2008-03-24 2009-03-23 Percutaneous preparation containing donepezil as active ingredient for treatment of dementia Ceased WO2009120002A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2008-0026952 2008-03-24
KR1020080026952A KR101454362B1 (en) 2008-03-24 2008-03-24 Transdermal preparation for the treatment of dementia comprising donepezil as an active ingredient

Publications (2)

Publication Number Publication Date
WO2009120002A2 WO2009120002A2 (en) 2009-10-01
WO2009120002A3 true WO2009120002A3 (en) 2009-12-23

Family

ID=41114447

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/001472 Ceased WO2009120002A2 (en) 2008-03-24 2009-03-23 Percutaneous preparation containing donepezil as active ingredient for treatment of dementia

Country Status (2)

Country Link
KR (1) KR101454362B1 (en)
WO (1) WO2009120002A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2713207C2 (en) * 2014-12-18 2020-02-04 Айкьюре Фармасьютикал Инк. Transdermal composition containing donepezil as active ingredient

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2652491T3 (en) * 2009-10-21 2018-02-02 Teikoku Seiyaku Co., Ltd. Preparation containing donedercil transdermal absorption
JP5766475B2 (en) * 2010-03-30 2015-08-19 日東電工株式会社 Patch preparation and method for producing the same
NZ605352A (en) 2010-06-30 2013-10-25 Nal Pharmaceuticals Ltd Process for producing glycosaminoglycans
TWI433904B (en) * 2011-01-12 2014-04-11 Taiwan Biotech Co Ltd Donepezil transdermal patch
KR101054317B1 (en) * 2011-01-28 2011-08-08 신신제약 주식회사 Percutaneous Absorbents Containing Rivastigmine
KR101964295B1 (en) * 2012-09-05 2019-04-01 주식회사 한독 Memantine Transdermal Delivery System Having Reduced Skin Irritation
KR101485822B1 (en) 2014-01-22 2015-01-23 주식회사 대웅제약 Transdermal drug delivery system comprising donepezil or its salt
CN106456562B (en) 2014-02-20 2020-01-31 安能泰制药有限公司 Transdermal drug delivery system containing donepezil
US10966936B2 (en) 2015-12-30 2021-04-06 Corium, Inc. Systems comprising a composite backing and methods for long term transdermal administration
CA3028436A1 (en) 2016-06-23 2017-12-28 Corium International, Inc. Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent
US9993466B2 (en) 2016-07-27 2018-06-12 Corium International, Inc. Donepezil transdermal delivery system
MX2019001104A (en) 2016-07-27 2019-10-02 Corium Int Inc Memantine transdermal delivery systems.
CN111132669A (en) * 2017-07-26 2020-05-08 考里安公司 Transdermal delivery systems with microporous membranes with solvent-filled pores
US11173132B2 (en) 2017-12-20 2021-11-16 Corium, Inc. Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point
KR102024996B1 (en) 2017-12-27 2019-09-25 동아에스티 주식회사 Percutaneous Absorption Preparation for Treating Dementia Comprising Donepezil
KR102115102B1 (en) 2018-12-21 2020-05-26 동아에스티 주식회사 Percutaneous Absorption Preparation Comprising Stabilized Donepezil
KR102372630B1 (en) 2019-05-15 2022-03-14 주식회사 대웅제약 A transdermal preparation comprising a high content of donepezil or a salt thereof
KR20210133816A (en) 2020-04-29 2021-11-08 신신제약 주식회사 Percutaneous absorption system comprising donepezil
KR102218593B1 (en) * 2020-05-13 2021-02-22 동아에스티 주식회사 Percutaneous Absorption Preparation Comprising Donepezil with Improved Stability

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11315016A (en) * 1998-03-03 1999-11-16 Eisai Co Ltd Preparation or suppository for percutaneous administration containing antidemential agent
US6677330B1 (en) * 1999-03-03 2004-01-13 Eisai Co., Ltd. Fluorides of 4-substituted piperidine derivatives
US20040258741A1 (en) * 2001-10-17 2004-12-23 Takaaki Terahara Percutaneous absorption preparations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5084496B2 (en) * 2005-02-04 2012-11-28 久光製薬株式会社 Transdermal patch

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11315016A (en) * 1998-03-03 1999-11-16 Eisai Co Ltd Preparation or suppository for percutaneous administration containing antidemential agent
US6677330B1 (en) * 1999-03-03 2004-01-13 Eisai Co., Ltd. Fluorides of 4-substituted piperidine derivatives
US20040258741A1 (en) * 2001-10-17 2004-12-23 Takaaki Terahara Percutaneous absorption preparations

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2713207C2 (en) * 2014-12-18 2020-02-04 Айкьюре Фармасьютикал Инк. Transdermal composition containing donepezil as active ingredient

Also Published As

Publication number Publication date
KR20090101667A (en) 2009-09-29
WO2009120002A2 (en) 2009-10-01
KR101454362B1 (en) 2014-10-23

Similar Documents

Publication Publication Date Title
WO2009120002A3 (en) Percutaneous preparation containing donepezil as active ingredient for treatment of dementia
JP6077596B2 (en) Ropinirole-containing patch and its package
JP6793648B2 (en) Transdermal preparation containing donepezil as an active ingredient
JP5951637B2 (en) Transdermal absorption preparation containing rivastigmine
JP5001271B2 (en) New tape formulation
EP2687205B1 (en) Fentanyl transdermal patch
JP5823510B2 (en) Ropinirole-containing patch and its package
CA2494361A1 (en) Hot melt tts for administering rotigotine
JP6453481B2 (en) Patch
JP2014177428A (en) Rotigotine percutaneous absorption type patch formulation containing rosin resin
JPWO2012077651A1 (en) Noradrenergic / specific serotonergic antidepressant-containing transdermal absorption patch
KR101868186B1 (en) Transdermal Patch
WO2005011662A1 (en) Adhesive patch
WO2006048939A1 (en) Nonaqueous preparation for percutaneous absorption containing nonsteroidal antiflammatory analgesic
CN109789104A (en) Transdermal delivery system comprising galanthamine or its salt
WO2014199455A1 (en) Percutaneous absorption type patch memantine preparation
JP2022530345A (en) Percutaneous treatment system
JP5842304B2 (en) External patch
JP2004067539A (en) Dermal administration plaster
JPWO2013183407A1 (en) Mirtazapine-containing transdermal absorption patch preparation
WO2005041967A1 (en) Transdermal preparations and method for relieving side effects in pergolide therapy
JP2018104418A (en) Rotigotine percutaneous absorption type patch formulation containing antipruritic agent
HK1186099B (en) Transdermal patch
HK1129574A1 (en) Transdermal patch containing isosorbide dinitrate and bisoprolol

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09724249

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09724249

Country of ref document: EP

Kind code of ref document: A2